Using blood data for the differential diagnosis and prognosis of motor neuron diseases: a new dataset for machine learning applications

Abstract

Early differential diagnosis of several motor neuron diseases (MNDs) is extremely challenging due to the high number of overlapped symptoms. The routine clinical practice is based on clinical history and examination, usually accompanied by electrophysiological tests. However, although previous studies have demonstrated the involvement of altered metabolic pathways, biomarker-based monitoring tools are still far from being applied. In this study, we aim at characterizing and discriminating patients with involvement of both upper and lower motor neurons (i.e., amyotrophic lateral sclerosis (ALS) patients) from those with selective involvement of the lower motor neuron (LMND), by using blood data exclusively. To this end, in the last ten years, we built a database including 692 blood data and related clinical observations from 55 ALS and LMND patients. Each blood sample was described by 108 analytes. Starting from this outstanding number of features, we performed a characterization of the two groups of patients through statistical and classification analyses of blood data. Specifically, we implemented a support vector machine with recursive feature elimination (SVM-RFE) to automatically diagnose each patient into the ALS or LMND groups and to recognize whether they had a fast or slow disease progression. The classification strategy through the RFE algorithm also allowed us to reveal the most informative subset of blood analytes including novel potential biomarkers of MNDs. Our results show that we successfully devised subject-independent classifiers for the differential diagnosis and prognosis of ALS and LMND with remarkable average accuracy (up to 94%), using blood data exclusively.

Evaluation of the Blood and Serum Biomarkers for the Prognosis and Progression of the ALS Disease by Eliminating the Effects of Aging

“…We have also evaluated blood biomarkers as potential biomarkers in the SOD1 WT and SOD1 G93A rats that have become a hot topic in a couple of years. RBC and MCH levels were suggested as possible early biomarkers of early stages of ALS by an in-silico study 33 . Additionally, decreased levels of RBC count have been reported as an early biomarker in ALS 34 .…”

The Interplay Between Neuroinfections, the Immune System and Neurological Disorders: A Focus on Africa

“…: percentage of monocytes, immunoglobulin M [IgM], and CD3 lymphocyte counts) or CSF (e.g. : Chitinase-3-like protein 1, Chitinase-3-like protein 2, Alpha-1-antichymotrypsin) raises the index of suspicion in favor of ALS, and may discriminate ALS from other MNDs ( 116 , 117 ). However, more research is needed to establish an appropriate test for ALS.…”

Machine Learning Solutions Applied to Amyotrophic Lateral Sclerosis Prognosis: A Review

“…Despite Greco et al (2021) aimed to find blood analytes to distinguish patients who have ALS from those with Lower Motor Neuron Disease (LMND), they also studied the classification of these patients with relation to their disease progression rates (High or Low). They analyzed clinic, demographic, and blood (108 analytes) data from 41 ALS patients.…”